Regeneron posts strong growth for 2012, beating analysts' estimates
15 February 2013
Recent Eylea growth in USA appears to be coming from expanded uptake among prescribers
7 January 2013
News briefs from Bayer, AstraZeneca and Valeant/Galderma
6 December 2012
EU Commission approves Bayer's Eylea for wet AMD and Abbott's Humira for pediatric Crohn's
28 November 2012
Access to many more medicines in Australia, as PBS list extended
28 October 2012
Japanese approvals for Eylea, Tresiba, Seebri and Aimix
1 October 2012
EMA backs Almirall's Constella; Bayer's Eylea recommended by CHMP
24 September 2012
Trial and uptake of Regeneron's Eylea continues to rise among US retinal specialists; report
24 July 2012
Australia latest to approve Bayer's Eylea
8 March 2012
Regeneron ups Eylea forecast, posts 2011 results
14 February 2012
Regeneron and Bayer’s Eylea backed by thought leaders for DME
13 February 2012
Roche unit in partial patent deal with Regeneron over Eylea; new indication for Avastin
4 January 2012
Bayer boasts four potential pipeline blockbusters
21 December 2011
Phase III trial of Regeneron and Bayer’s Eylea initiated in China
29 November 2011
US FDA delays decision on Regeneron’s wet AMD drug Eylea
18 August 2011
AMD and diabetic retinopathy drugs market to reach $5.08 billion by 2014, says Visiongain
11 July 2011
Showing 1-26 of 26 articles
- 1
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
